Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2018 | Finding the right targets for CAR T-cell therapy in AML

Speaking from the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary, Arnold Ganser, MD, from the Hannover Medical School, Hannover, Germany, explains how CAR T-cell therapy might not prove effective in acute myeloid leukemia patients if healthy hematopoietic stem cells are targeted. His research group is now looking into special gene-modified autologous dendritic cells that have increased activity towards WT1, a tumor antigen that is expressed at high levels in various acute and chronic leukemias.